Literature DB >> 4246140

Australia antigen (a hepatitis-associated antigen): purification and physical properties.

I Millman, L A Loeb, M E Bayer, B S Blumberg.   

Abstract

Australia antigen [Au(1)], a particle associated with viral hepatitis, was isolated from the plasma of a patient with chronic anicteric hepatitis and leukemia who had received radioactive phosphorus. We have found that the immunoreactivity and appearance of Au(1) in the electron microscope were not altered by treatment with enzymes including trypsin, pronase, lipase, phospholipase C, ribonuclease, deoxyribonuclease, amylase, and neuraminidase. In contrast, other serum constituents were degraded by these enzymes. Therefore, treatment of the patient's plasma with many enzymes was exploited as an initial step for the isolation of Au(1). Subsequently, Au(1) was purified from the enzyme-treated (32)P-labeled plasma by gel filtration through Sephadex G-200 and centrifugation through sucrose and in cesium chloride gradients. There were no detectable human serum components in the purest fractions, as tested by immunoelectrophoresis and immunodiffusion. The density of the purified Au(1) was 1.21 in CsCl. The particle measured about 200 A in diameter, was predominantly spherical in shape and appeared to be composed of subunits. Nucleic acids were not detected by spectrophotometric, radiochemical, and chemical analyses. Immunoreactivity of purified Au(1) was destroyed by heating for 1 hr at 85 degrees C but was stable at 56 degrees C. Treatment with Carnoy's solution (3 parts ethanol:1 part glacial acetic acid) followed by pronase disrupted the particles as seen with the electron microscope. These findings, combined with other published information on Australia antigen and viral hepatitis, suggest that the bulk of Australia antigen in the blood of this patient is an incomplete virus or virus capsid.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 4246140      PMCID: PMC2138848          DOI: 10.1084/jem.131.6.1190

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  16 in total

1.  Australia antigen and acute viral hepatitis.

Authors:  W T London; A I Sutnick; B S Blumberg
Journal:  Ann Intern Med       Date:  1969-01       Impact factor: 25.391

2.  Anicteric hepatitis associated with Australia antigen. Occurrence in patients with Down's syndrome.

Authors:  A I Sutnick; W T London; B J Gerstley; M M Cronlund; B S Blumberg
Journal:  JAMA       Date:  1968-09-02       Impact factor: 56.272

3.  Particles associated with Australia antigen in the sera of patients with leukaemia, Down's Syndrome and hepatitis.

Authors:  M E Bayer; B S Blumberg; B Werner
Journal:  Nature       Date:  1968-06-15       Impact factor: 49.962

4.  A serum antigen (Australia antigen) in Down's syndrome, leukemia, and hepatitis.

Authors:  B S Blumberg; B J Gerstley; D A Hungerford; W T London; A I Sutnick
Journal:  Ann Intern Med       Date:  1967-05       Impact factor: 25.391

5.  Relation of Australia and SH antigens.

Authors:  A M Prince
Journal:  Lancet       Date:  1968-08-24       Impact factor: 79.321

6.  An antigen detected in the blood during the incubation period of serum hepatitis.

Authors:  A M Prince
Journal:  Proc Natl Acad Sci U S A       Date:  1968-07       Impact factor: 11.205

7.  Australia antigen detected in the nuclei of liver cells of patients with viral hepatitis by the fluorescent antibody technic.

Authors:  I Millman; V Zavatone; B J Gerstley; B S Blumberg
Journal:  Nature       Date:  1969-04-12       Impact factor: 49.962

8.  Observations on Australia antigen in Japanese.

Authors:  K Okochi; S Murakami
Journal:  Vox Sang       Date:  1968       Impact factor: 2.144

9.  Hepatitis and leukemia: their relation to Australia antigen.

Authors:  B S Blumberg; A I Sutnick; W T London
Journal:  Bull N Y Acad Med       Date:  1968-12

10.  Further studies on a "new" human isoprecipitin system (Australia antigen).

Authors:  H J Alter; B S Blumberg
Journal:  Blood       Date:  1966-03       Impact factor: 22.113

View more
  25 in total

Review 1.  Animal models and the molecular biology of hepadnavirus infection.

Authors:  William S Mason
Journal:  Cold Spring Harb Perspect Med       Date:  2015-04-01       Impact factor: 6.915

2.  Large-scale purification of hepatitis B surface antigen.

Authors:  J Vnek; A M Prince
Journal:  J Clin Microbiol       Date:  1976-06       Impact factor: 5.948

Review 3.  The chimpanzee model for hepatitis B virus infection.

Authors:  Stefan F Wieland
Journal:  Cold Spring Harb Perspect Med       Date:  2015-06-01       Impact factor: 6.915

4.  HBsAg uptake by macrophages in vitro: an immunofluorescence study.

Authors:  G Pepe; A Cifarelli; F Paradisi; F De Ritis
Journal:  Experientia       Date:  1979-03-15

Review 5.  Hepatitis-associated (Australia) antigen: a review.

Authors:  J B Simon
Journal:  Can Med Assoc J       Date:  1971-09-18       Impact factor: 8.262

6.  Subspecificities of Australia antigen.

Authors:  S K Sama; L Krishnamurthy; S Gurdeep
Journal:  Am J Dig Dis       Date:  1974-06

7.  Concentration and purification of hepatitis B antigen with polyethylene glycol and polyelectrolyte 60, a cross-linked copolymer of isobutylene maleic anhydride.

Authors:  E De Rizzo; R Pandey; C Wallis; J L Melnick
Journal:  Infect Immun       Date:  1972-09       Impact factor: 3.441

8.  Reduction and reoxidation of Australia antigen: loss and reconstitution of particle structure and antigenicity.

Authors:  N Sukeno; R Shirachi; J Yamaguchi; N Ishida
Journal:  J Virol       Date:  1972-01       Impact factor: 5.103

9.  Cell-mediated immune response to hepatitis B antigen in patients with liver disease.

Authors:  M J Gerber; A Phuangsab; S B Vittal; D Dourdourekas; F Steigmann; B F Clowdus
Journal:  Am J Dig Dis       Date:  1974-07

10.  Comparative biophysical studies of hepatitis B antigen, subtypes adw and ayw.

Authors:  R Chairez; F B Hollinger; J P Brunschwig; G R Dreesman
Journal:  J Virol       Date:  1975-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.